Ultime notizie per Immuneering (NASDAQ:IMRX) Azioni

IMMUNEERING CORP - CLASS A

Immuneering

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

WIIM

APOG

Apogee Therapeutics shares are trading higher after the company released 16-week data from Part A of the Phase 2 APEX clinical trial of APG777 for moderate-to-severe atopic dermatitis.

Mogo Inc. ("Mogo" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOGO#NASDAQ">MOGO</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/MOGO#TSX">MOGO</a>), a Canadian financial technology company offering solutions across wealth, lending, and payments, today announced that it repurchased approximately 2% of its currently issued and outstanding shares during the second quarter of 2025 under its previously announced NASDAQ buyback program.
During the quarter, the Company repurchased 523,091 common shares at an average price of approximately US$1.44 per share. The shares were purchased for cancellation, reducing the total number of shares outstanding to approximately 24 million as of June 30, 2025.
"This repurchase activity reflects our continued commitment to disciplined capital allocation and long-term shareholder value," said Greg Feller, President &amp; Co-Founder. "We view share buybacks as a strategic use of capital when we believe our stock is trading meaningfully below intrinsic value."
Bitcoin Hurdle Rate Now Guides Capital Deployment
In alignment with the Company's recently announced Bitcoin treasury strategy, all future capital allocation decisions, including share repurchases, will be evaluated against a Bitcoin hurdle rate. Under this framework, capital will only be deployed into opportunities expected to outperform the long-term return profile of holding Bitcoin.
"If we believe repurchasing our shares offers greater long-term value than holding Bitcoin, we will act accordingly," added Greg Feller. "If not, we will preserve capital or continue building our Bitcoin reserve."

News

Buybacks

MOGO

TSX:MOGO

Mogo Buys Back 2% of Shares, Ties Future Capital Moves to Bitcoin Performance

ARTL

Artelo Biosciences shares are trading higher after the company announced preclinical efficacy with ART12.11 in a stress-induced depression model.

Raymond James analyst Michael Rose upgrades U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) from Outperform to Strong Buy and raises the price target from $51 to $57.

Upgrades

Price Target

Analyst Ratings

Raymond James Upgrades U.S. Bancorp to Strong Buy, Raises Price Target to $57

Shares of CoreCivic and Geo Group are trading higher in reaction to ICE funding in President Trump's spending bill.

MOH stock has given up its prior loss. Molina shares were trading lower after the company guided Q2 EPS to $5.50 vs the $6.21 estimate and cut its full-year EPS outlook amid rising medical costs.

CICC initiates coverage on Rockwell Automation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) with a Outperform rating and announces Price Target of $381.

Initiation

CICC Initiates Coverage On Rockwell Automation with Outperform Rating, Announces Price Target of $381

The U.S. Food and Drug Administration (FDA) on Monday approved KalVista Pharmaceuticals Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALV#NASDAQ">KALV</a>) Ekterly&nbsp;(sebetralstat) for acute attacks of hereditary angioedema (HAE) in adult and pediatric patients <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/b46270261/kalvista-pharmaceuticals-announces-fda-approval-of-ekterly-sebetralstat-first-and-only-oral-on-dem" rel="noreferrer noopener">aged 12 years and older</a>.
Ekterly is the first and only oral on-demand treatment for HAE. HAE is characterized by recurrent episodes of severe swelling (angioedema).
The efficacy and safety of Ekterly were established by the results from KalVista&#8217;s phase 3 KONFIDENT clinical trial, which was the largest clinical trial program ever conducted in HAE, the company said in a statement on Monday.
Also Read: <a target="_blank" href="https://www.benzinga.com/m-a/25/06/46142142/biocryst-just-ditched-its-europe-business-heres-why-investors-are-cheering" rel="noreferrer noopener">BioCryst Just Ditched Its Europe Business — Here&#8217;s Why Investors Are Cheering</a>
Data from KONFIDENT was published in the&nbsp;New England Journal of Medicine&nbsp;in May 2024, showing that Ekterly achieved significantly faster symptom relief, reduced attack severity and resolution than placebo, and was well-tolerated with a safety profile similar to placebo.
The trial randomized 136 HAE patients.
These results were further supported by the more real-world KONFIDENT-S open-label extension trial, which, as of September 2024, showed that Ekterly enabled patients to treat attacks in a median of 10 minutes following onset.
The most recent data from KONFIDENT-S show that the beginning of symptom relief occurred in a median of 1.3 hours among attacks involving the larynx and the abdomen and for breakthrough attacks among patients receiving long-term prophylaxis.
KalVista will launch Ekterly in the U.S. immediately, and physicians can begin writing prescriptions today.
Due to heavy workload and limited resources, the FDA missed the PDUFA (Prescription Drug User Fee Act) goal date of 17 June for the New Drug Application (NDA) <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45934266/kalvista-pharmaceuticals-announces-fda-will-not-meet-pdufa-goal-date-for-sebetralstat-nda-for-here" rel="noreferrer noopener">for sebetralstat for HAE</a>.
In other developments, KalVista Pharmaceuticals <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46111778/kalvista-pharmaceuticals-enters-into-licensing-agreement-with-pendopharm-to-commercialize-sebetral" rel="noreferrer noopener">also granted Pendopharm</a>, a division of Pharmascience Inc., exclusive rights to manage the regulatory approval and commercialization of sebetralstat in Canada. The financial terms of this agreement were not disclosed.
Meanwhile, Intellia Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) is working on a different kind of treatment for HAE: an investigational in vivo CRISPR-based <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41524915/why-is-gene-therapy-focused-intellia-therapeutics-stock-trading-lower-on-thursday" rel="noreferrer noopener">gene editing therapy</a> called NTLA-2002.
In vivo gene editing means the gene-editing tools are delivered directly into the patient&#8217;s body to make changes to their DNA, aiming for a one-time, potentially curative treatment.
Intellia released promising Phase 2 data from its ongoing Phase 1/2 study of NTLA-2002 in October 2024. A single dose of NTLA-2002 showed mean monthly attack rates relative to placebo were reduced by 75% and 77% for the 25 mg and 50 mg arms during weeks 1–16 and by 80% and 81% during weeks 5–16, respectively.
In the 50 mg arm, eight of 11 patients experienced a complete response after a single dose of NTLA-2002, with no attacks at all during the 16-week primary observation period; these eight patients continued to be attack-free through the latest follow-up (median of eight months), and no subsequent treatment has been required.
Price Action: KALV stock is trading higher by 15.9% to $13.89 premarket at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/07/46269816/wegovy-zepbound-prices-drop-but-most-patients-still-cant-afford-long-term-use-coverage-is-not-the-same-as-access-says-expert" target="_blank" rel="noreferrer noopener">Wegovy, Zepbound Prices Drop, But Most Patients Still Can&#8217;t Afford Long-Term Use: &#8216;Coverage Is Not The Same As Access,&#8217; Says Expert</a></li>
</ul>
Photo by Tada Images via Shutterstock

Biotech

Health Care

Movers

General

KALV

NTLA

FDA Approves KalVista's Ekterly As First Oral On-Demand Treatment For Rare Swelling Disease

Artelo Biosciences, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced the presentation of compelling new preclinical data on its Cannabidiol (CBD) and Tetramethylpyrazine (TMP) cocrystal drug candidate, ART12.11, at the <a href="https://www.globenewswire.com/Tracker?data=oolR50karCmYlxhUqeu5BeXwq-dPKU2Yy4DyRK5SbZGUW8S0iUG0NfoQ4GZvIEIHIYfdgYqzMHDuJhxfZM6ZYM57VQzfR1l30i5AqASFTDjTnTmdf81-unrsKTsHgPxLcqR3D-jPmQCdqQJy65wSqQ8ud0fFR9d6Awr2ynM3sMU=">35th Annual International Cannabinoid Research Society (ICRS) Symposium</a>, taking place July 6–10 in Bloomington, Indiana.
The poster, titled "ART12.11, A Novel Cannabidiol:Tetramethylpyrazine Cocrystal, Alleviates Stress-Induced Depressive Symptoms," is being presented today by Matt Jones, a scientist working in the laboratory of Professor Steven Laviolette at the University of Western Ontario, Canada. The data highlight ART12.11's unique dual-action profile in improving depression-related behaviors in animals and reversing cognitive deficits associated with chronic stress. These are key differentiators that position ART12.11 as a potential next-generation treatment candidate in the multi-billion-dollar antidepressant market.
Highlights:
<ul>
<li>Robust Antidepressant-like Effects: A 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress. The data with ART12.11 demonstrated efficacy on par with sertraline (Zoloft), a leading selective serotonin reuptake inhibitor (SSRI).</li>
<li>Restoration of Hedonic and Social Behaviors: Like sertraline, ART12.11 improved sucrose preference and social motivation, which are established behavioral markers of depressive-like states, to near-baseline levels.</li>
<li>Superior Cognitive Restoration: Unlike sertraline, ART12.11 reversed stress-induced deficits in both spatial and short-term memory without negatively impacting social memory.</li>
<li>Differentiated Therapeutic Profile: These findings underscore ART12.11's potential as a highly differentiated candidate for treating depression and anxiety, especially in patients where cognitive dysfunction occurs, which is a known limitation of existing SSRI therapies.</li>
</ul>

Artelo Unveils New Depression Drug Data, Shows Zoloft-Level Efficacy With Added Cognitive Benefits

Chardan Capital analyst James McIlree maintains VinFast Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) with a Buy and maintains $5.5 price target.

Chardan Capital Maintains Buy on VinFast Auto, Maintains $5.5 Price Target

HUB Cyber Security Ltd. (NASDAQ:<a href="https://www.benzinga.com/stock/HUBC#NASDAQ">HUBC</a>) ("HUB" or the "Company"), a global leader in zero-trust confidential computing, secured data fabric infrastructure and AI-native security orchestration, today announced the appointment of Aviv Eyal as Head of its newly formed Digital Asset Infrastructure Division.
This move reflects HUBC's strategic commitment to advancing secure, scalable infrastructure for the decentralized economy. By expanding its platform to serve the next generation of digital asset institutions, HUBC is reinforcing its leadership in high-compliance, AI-native cybersecurity.
Aviv Eyal brings over 20 years of experience in digital encryption, information assurance and decentralized systems, with a proven track record designing secure, scalable digital asset infrastructure. He has led core innovation efforts at Spacemesh, Subnet, and other ventures focused on trust, privacy, and resilience at scale. At HUB, Aviv plays a central role in the development of our zero-trust architecture and secured data fabric, supporting the Company's broader mission to deliver programmable, tamper-resistant infrastructure for regulated industries.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

HUBC

HUB Cyber Taps Aviv Eyal to Lead New Digital Asset Division, Expands Crypto Security Focus

Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) will release earnings results for the second quarter, before the <a href="https://www.benzinga.com/quote/C/earnings">opening bell on Tuesday, July 15</a>.
Analysts expect the New York-based company to report quarterly earnings at $1.63 per share, up from $1.57 per share in the year-ago period. Citigroup projects to report quarterly revenue of $20.83 billion, compared to $20.14 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On June 16, Citigroup announced $650 million redemption of floating rate notes due 2026.
Citigroup shares gained 2.3% to close at $88.72 on Thursday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/c/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Morgan Stanley analyst Betsy Graseck maintained an Overweight rating and raised the price target from $94 to $103 on July 3, 2025. This analyst has an accuracy rate of 61%.</li>
<li>Goldman Sachs analyst Richard Ramsden maintained a Buy rating and boosted the price target from $85 to $96 on July 2, 2025. This analyst has an accuracy rate of 72%.</li>
<li>Evercore ISI Group analyst Glenn Schorr maintained an In-Line rating and boosted the price target from $76 to $77 on July 2, 2025. This analyst has an accuracy rate of 71%.</li>
<li>B of A Securities analyst Ebrahim Poonawala maintained a Buy rating and raised the price target from $89 to $100 on June 26, 2025. This analyst has an accuracy rate of 68%.</li>
<li>Oppenheimer analyst Chris Kotowski maintained an Outperform rating and boosted the price target from $91 to $94 on April 28, 2025. This analyst has an accuracy rate of 83%</li>
</ul>
Considering buying C stock? Here&#8217;s what analysts think:
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/c/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07020329/image-53-1024x583.png" alt="" class="wp-image-974073" style="width:590px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07020329/image-53-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07020329/image-53-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07020329/image-53-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07020329/image-53.png 1112w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46243448/cramer-doesnt-recommend-titan-international-joby-aviation-soars-after-milestone-flight">Cramer Doesn&#8217;t Recommend Titan International, Joby Aviation Soars After Milestone Flight</a> </li>
</ul>
Photo via Shutterstock

Earnings

Trading Ideas

Top Wall Street Forecasters Revamp Citigroup Expectations Ahead Of Q2 Earnings

<ul>
<li>AUM &amp; Continued Monthly Net Inflows: Valour reported assets under management (AUM) of US$771M (C$1.04B) as of June 30, 2025, reflecting a 5% decrease month-over-month. Net inflows for May remained strong at US$4.5.M (C$6.2M), bringing year-to-date inflows to US$75.9M (C$105.5M)—underscoring accelerating investor demand for Valour's ETPs.</li>
<li>Strong Financial Position &amp; Treasury Strategy: The company maintains a total cash, USDT, and treasury balance of US$62.4M (C$85M), comprising US$14M (C$19M) in cash and USDT, reflecting a 17% decrease from the previous month, and US$48.4M (C$66M) in its digital asset treasury, a 8.7% decrease from the previous month as of June 30, 2025.</li>
<li>2025 Revenue Guidance: DeFi Technologies' fiscal 2025 revenue guidance remains US$201.07M (C$285.6M).</li>
</ul>

DEFT

DeFi Technologies' FY25 Revenue Guidance Remains $201.07M

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the industrials sector.
<h3 class="wp-block-heading">United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.50%</li>
<li>UBS analyst Thomas Wadewitz maintained a Buy rating and cut the price target from $128 to $124 on July 2, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Oppenheimer analyst Scott Schneeberger maintained an Outperform rating and cut the price target from $126 to $114 on April 30, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: United Parcel Service is strategically navigating a challenging economic landscape, focusing intensely on internal efficiencies and cost reduction to bolster profitability and deliver higher returns for investors.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest UPS news. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0707"><img loading="lazy" decoding="async" width="911" height="821" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07073058/image-60.png" alt="" class="wp-image-974619" style="width:540px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07073058/image-60.png 911w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07073058/image-60-300x270.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07073058/image-60-768x692.png 768w" sizes="(max-width: 911px) 100vw, 911px" /></a></figure>
<h3 class="wp-block-heading">Karat Packaging Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.40%</li>
<li>Truist Securities analyst Jake Bartlett maintained a Hold rating and raised the price target from $28 to $31 on May 12, 2025. This analyst has an accuracy rate of 75%.</li>
<li>William Blair analyst Ryan Merkel downgraded the stock from Outperform to Market Perform on Jan. 2, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On June 10, Karat Packaging announced it priced a secondary offering of 1.5 million shares at $27 per share.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest KRT <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0707">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0707"><img loading="lazy" decoding="async" width="902" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07073143/image-61.png" alt="" class="wp-image-974621" style="width:640px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07073143/image-61.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07073143/image-61-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07073143/image-61-768x704.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">Copa Holdings, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPA#NYSE">CPA</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 5.86%</li>
<li>TD Cowen analyst Thomas Fitzgerald maintained a Buy rating and cut the price target from $145 to $130 on Aug. 9, 2024. This analyst has an accuracy rate of 66%.</li>
<li>Deutsche Bank analyst Michael Linenberg maintained a Buy rating and slashed the price target from $145 to $130 on Aug. 8, 2024. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: Copa Holdings is expected to post its second-quarter results on Aug. 6.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0707">CPA news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0707"><img loading="lazy" decoding="async" width="916" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07073212/image-1-11.png" alt="" class="wp-image-974623" style="width:647px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07073212/image-1-11.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07073212/image-1-11-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07073212/image-1-11-768x698.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46243448/cramer-doesnt-recommend-titan-international-joby-aviation-soars-after-milestone-flight">Cramer Doesn&#8217;t Recommend Titan International, Joby Aviation Soars After Milestone Flight</a> </li>
</ul>
Photo via Shutterstock

Dividends

Pre-Market Outlook

Wall Street's Most Accurate Analysts Spotlight On 3 Industrials Stocks With Over 5% Dividend Yields

Jasper Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), is reporting updated data from Company's BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with CSU and providing an update on the program. Briquilimab administration resulted in deep and rapid disease control in the 240mg and 360mg single-dose cohorts, with 8 of 9 (89%) of participants enrolled across both cohorts achieving a complete response, and with 7 of 9 (78%) achieving a clinical response by week 2. In addition, BEACON participants who rolled over into the open-label extension study dosing at 180mg Q8W demonstrated robust clinical efficacy with 8 of 11 (73%) participants achieving a complete response at 12 weeks.
Results from the 240mg Q8W and the 240mg followed by 180mg Q8W dose cohorts appear to be confounded by an issue with one drug product lot used in those cohorts, with 10 of the 13 patients dosed with drug from the lot in question. The Company is investigating the drug product lot in question and expects to have the results of that investigation in the coming weeks. Key observations noted in those 10 patients were lower than expected drops in mean tryptase levels and no discernable impact on UAS7 scores. The 2 participants enrolled in the cohorts that have been confirmed as being dosed with drug product from a different lot both achieved complete response.
New drug product is being provided to clinical sites to transition the 10 patients who were initially dosed with drug from the lot in question to drug product for their next administration that has demonstrated efficacy in earlier and ongoing cohorts. The Company also plans to enroll an additional 10-12 patients in total across the 240mg Q8W and the 240mg followed by 180mg Q8W cohorts to ensure a robust data set to inform the Phase 2b CSU study. Data from the additional BEACON patients is expected in 4Q 2025 and commencement of the Phase 2b study is now expected in mid-2026.
The Company has also determined that the drug product lot in question was used to treat participants enrolled in the ETESIAN trial evaluating briquilimab in asthma. As a result, and in order to focus resources on advancing briquilimab in CSU, the Company is halting the study and pausing development in asthma. In addition, the Company is halting development in SCID and will be implementing a number of other cost cutting measures, including a potential restructuring, to extend runway and reduce expenses.

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

Jasper Reports 89% Response Rate in Urticaria Study, Halts Asthma Program After Drug Lot Issue

HIGHLIGHTS
<ul>
<li>X-ray transmission (XRT) ore sorter testwork of a ~80 tonne sample taken from the Cariboo underground achieved positive results consistent with 2025 FS parameters</li>
<li>42-55% waste rejection with 84-89% gold recovery achieved by sorting mid-size and oversize sample material including 10–30 mm and 30–70 mm size fractions, respectively
<ul>
<li>Encouraging results from testing the previously unassessed 6–10 mm size fraction, made possible by recent advancements in AI, demonstrated 59% waste rejection and 95% gold recovery, highlighting a potential opportunity for future optimization</li>
</ul>
</li>
<li>2.0-2.1 upgrade ratio consistent with 2025 FS assumption of 1.95</li>
<li>New testwork represents a significantly larger data set, with previous sorting totalling ~5 tonnes and completed largely on material sourced from drill core</li>
<li>76% of the contained gold in the test sample estimated to report to the fines fraction (&lt;10 mm)</li>
<li>Flowsheet optimization work, including a variability study to refine assumptions across the deposit, is contemplated to be completed as part of detailed engineering</li>
</ul>
MONTREAL, July 07, 2025 (GLOBE NEWSWIRE) -- Osisko Development Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ODV#NYSE">ODV</a>, TSXV:<a class="ticker" href="https://www.benzinga.com/stock/ODV#TSXV">ODV</a>) ("Osisko Development" or the "Company") is pleased to announce positive results from an ore sorting testing program conducted on a bulk tonnage sample of mineralized material extracted from its permitted, 100%-owned Cariboo Gold Project ("Cariboo" or the "Project"), located in central British Columbia ("B.C."), Canada. The testwork results demonstrate gold recoveries, mass pull, and upgrade ratios consistent with the assumptions outlined in the 2025 FS (as defined herein), and were conducted on a significantly larger scale than previous programs. Importantly, positive results on a previously untested smaller 6–10 mm size fraction may represent a meaningful opportunity for flowsheet optimization.

TSXV:ODV

Osisko Reports Results From Ore Sorting Testing Program Conducted On Bulk Tonnage Sample Of Mineralized Material Extracted From Cariboo Gold Project In Central British Columbia

Organon's VTAMA Granted Strong Recommendation By American Academy Of Dermatology In Updated 2025 Guidelines For Adult Atopic Dermatitis

AIFU Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFU#NASDAQ">AIFU</a>) (the "Company" or "AIFU"), a leading AI-driven independent financial services platform in China, today announced that it has entered into a definitive share purchase agreement (the "Agreement") with certain investors, pursuant to which the investors have agreed to subscribe for, and the Company has agreed to issue and sell to the investors, (i) an aggregate of 10,000,000 Class A ordinary shares, par value US$0.4 per share, of the Company, at a price of $3.156 per share (the "Per Share Purchase Price") (the "Share Issuance"), and (ii) a warrant to purchase up to 20,000,000 additional Class A ordinary shares of the Company. 50% of the warrant will be exercisable at 200% of the Per Share Purchase Price, with the remaining 50% exercisable at 250%. The transaction is expected to generate approximately $31.6 million in gross proceeds from the Share Issuance.
Upon closing of the Share Issuance, the Company will have a total of 15,870,271 ordinary shares outstanding, consisting of 13,370,271 Class A ordinary shares and 2,500,000 Class B ordinary shares. Assuming no exercise of the warrant, the two largest investors in this transaction are expected to hold approximately 24.6% and 19.5% of the Company's total outstanding shares, respectively, representing 1.5% and 1.2% of the total voting power, respectively.

Offerings

AIFU

AIFU Raises $31.6M in Share Sale, Grants Investors Warrants for Up to 20M More Shares

QIPT

Quipt Home Medical Acquires A Full-Service Durable Medical Equipment Provider Owned By Ballad Health For $1.6M Plus Value Of Accounts Receivable And Inventory At closing

Canaccord Genuity analyst Joseph Vafi initiates coverage on Chime Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHYM#NASDAQ">CHYM</a>) with a Buy rating and announces Price Target of $40.

Comments

Immuneering

Notizie

Ultime notizie per Immuneering (NASDAQ:IMRX) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO